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Bordetella avium is thought to be strictly an avian 
pathogen. However, 16S rRNA gene sequencing identi-
ﬁ  ed 2 isolates from 2 humans with respiratory disease as 
B. avium and a novel B. avium–like strain. Thus, B. avium 
and B. avium–like organisms are rare opportunistic human 
pathogens.
S
everal  Bordetella species have been associated with 
respiratory disease in humans. Although B. avium is 
thought to be strictly an animal pathogen that causes tra-
cheobronchitis in wild and domesticated birds (1,2), infec-
tions in birds share many of the clinical and histopathologic 
features of disease in mammals caused by B. pertussis and 
B. bronchiseptica (3). Human cases of respiratory disease 
associated with B. avium have only recently been reported 
in patients with cystic ﬁ  brosis (4). We describe 2 isolates, 
B. avium and a novel strain resembling B. avium, isolated 
from 2 patients with pneumonia, thereby demonstrating 
that B. avium and B. avium–like organisms are opportunis-
tic human pathogens.
The Cases
Patient 1, a 68-year-old man with left lower lobe pneu-
monia and hemoptysis, sought care at a community hos-
pital. The patient had a history of end-stage renal disease 
requiring hemodialysis, chronic obstructive pulmonary 
disease (COPD), long-term tobacco use, and ischemic car-
diomyopathy being treated with anticoagulation. He had a 
10-day history of increasing shortness of breath and cough 
associated with mild hemoptysis. The initial chest radio-
graph demonstrated an extensive left-sided inﬁ  ltrate, which 
progressively worsened; the patient ultimately required 
endotracheal intubation and mechanical ventilation. Bron-
choscopy showed purulent secretions in the left mainstem 
bronchus, complete obstruction of the bronchus, and frothy 
secretions in the right airways. Gram-stained bronchoalve-
olar lavage (BAL) ﬂ  uid showed many polymorphonuclear 
leukocytes but no organisms. Routine bacterial culture of 
the ﬂ  uid isolated a pure culture that was phenotypically 
identiﬁ  ed by API NFT rapid test strip (bioMérieux, Hazel-
wood, MO, USA) as B. avium. Antimicrobial drug–suscep-
tibility testing performed using Etest (AB Biodisk, Solna, 
Sweden) resulted in the following MICs: ceftriaxone 2 μg/
mL, azithromycin 4 μg/mL, piperacillin/tazobactam 0.125/4 
μg/mL. The patient was initially treated with azithromycin 
and ceftriaxone and completed empiric therapy with pip-
eracillin/tazobactam and vancomycin. By day 7, the pa-
tient’s respiratory status improved enough that he could be 
extubated. Follow-up chest radiographs showed substantial 
resolution of the left-sided inﬁ  ltrates, and on day 11, the 
patient was discharged to a rehabilitation care facility.
Patient 2, a 61-year-old homeless man, was admitted 
to the Houston DeBakey Veteran Affairs Medical Center 
with a 4-month history of productive cough and a 1-month 
history of sporadic hemoptysis. He denied fever, chills, 
shortness of breath, and chest pain. His medical history 
included COPD, pulmonary tuberculosis, and long-term 
use of tobacco and alcohol. HIV ELISA result was nega-
tive. Chest radiographs and computed tomography scan 
showed marked emphysematous changes with bullae in the 
posterior left lobe, numerous calciﬁ  ed granulomas compat-
ible with old granulomatous disease in the left lung, and 
pleural thickening and reaction in the left apex. A lobu-
lated 2-cm soft tissue density in 1 of these cavities was also 
identiﬁ  ed. No acute inﬁ  ltrates were seen. The patient began 
treatment for COPD and for suspected pulmonary tuber-
culosis (ethambutol 1,600 mg/day, rifampicin 600 mg/day, 
pirazinamide 1,500 mg/day, and isoniazid 300 mg/day). 
Gram-stained BAL ﬂ  uid showed many polymorphonuclear 
leukocytes and small gram-negative rods. Routine bacterial 
culture of BAL ﬂ  uid isolated a pure culture that was identi-
ﬁ  ed as Bordetella spp. but that could not be identiﬁ  ed to 
the species level by API NFT rapid test strip. Susceptibil-
ity testing was performed by using the Kirby-Bauer disk-
diffusion method. Although no susceptibility guidelines for 
Bordetella spp. have been established, the isolate appeared 
to be sensitive to amikacin, trimethoprim-sulfamethox-
azole, gentamicin, ceftazidime, and imipenem and resistant 
to ampicillin, ampicillin/sulbactam, and aztreonam. An 
oral cephalosporin drug was added to the patient’s regimen. 
Three sputum samples were negative for acid-fast bacilli, 
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and treatment for tuberculosis was discontinued. The pa-
tient was discharged 9 days after hospital admission.
Isolates of nonlactose fermenting, small, gram-negative 
rods were recovered from BAL ﬂ  uid by using trypticase soy 
agar supplemented with 5% sheep blood, chocolate agar, 
and MacConkey agar incubated at 35°C in 5% CO2. The 
isolate from patient 1 was phenotypically consistent with 
B. avium (catalase positive, oxidase positive, nitrate reduc-
tion negative, urease negative). The isolate from patient 2 
was phenotypically inconsistent with all other well-charac-
terized Bordetella spp. (catalase positive, oxidase positive, 
nitrate reduction positive, urease negative) and could not be 
phenotypically identiﬁ  ed to the species level.
Sequence analysis was performed by PCR targeting 
the 16S rRNA gene as previously described (5). Samples 
were prepared by using the ABI PRISM BigDye Termi-
nator Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA, USA), and sequencing reactions were performed 
by using the ABI PRISM 3100 Analyzer according to man-
ufacturer’s instructions. Sequences were aligned by us-
ing Sequencher software and were submitted to GenBank 
BLAST database. The sequence from patient 1 was geneti-
cally identical to B. avium type strain ATCC 35086 (477 
bp evaluated, 100% sequence similarity), and the sequence 
from patient 2 was related to B. avium type strain ATCC 
35086 (509 bp evaluated, 98% sequence similarity [sub-
mitted as GenBank accession no. EU352642]). Several 16S 
rRNA gene sequences of type strains from the genus Bor-
detella were retrieved from GenBank, and a phylogenetic 
tree was constructed by using a neighbor-joining algorithm 
with Achromobacter xylosoxidans xylosoxidans as the out-
group (Figure). Concise alignment of the sequence from 
patient 2 showed 11-bp and 15-bp differences compared 
with B. avium (type strain ATCC 35086) and B. trematum 
(type strain DSM 11334), respectively. Thus, it represents 
a novel uncharacterized strain most closely related to B. 
avium (i.e., B. avium–like; Figure). Both the genotype of B. 
avium and the novel strain are distinguishable from other 
Bordetella spp. according to 16S rRNA gene sequencing of 
the ﬁ  rst 500 bp (≈2% bp difference). This ﬁ  nding is in con-
trast to the indistinguishable sequences of B. pertussis, B. 
parapertussis, B. bronchiseptica, and the closely related B. 
homlseii, which can be a limitation of 16S rRNA gene se-
quencing for the genus Bordetella, particularly when only 
the ﬁ  rst 500 bp are evaluated (Figure).
Conclusions
Although the ﬁ  rst report of human disease associated 
with B. avium was recently described in patients with cystic 
ﬁ  brosis (4), the role of B. avium in respiratory infection 
as opposed to colonization in patients with cystic ﬁ  brosis 
is unclear. The cases in this report provide a more direct 
clinical association of human respiratory infection and B. 
avium and B. avium–like organisms. Each of the 2 isolates 
was obtained in pure culture from BAL ﬂ  uid. Although 
neither patient was conventionally immunocompromised 
(e.g., no HIV, hematologic disorders, or immunosuppres-
sive therapy), each was an older person who had underly-
ing pulmonary problems along with other medical condi-
tions, and each belonged to a patient population typically 
susceptible to opportunistic infections. Each patient had 
signs and symptoms clinically consistent with respiratory 
syndromes caused by Bordetella, and each responded to 
treatment. Clinicians should be aware that human infec-
tions with B. avium may pose some antimicrobial drug 
treatment challenges. A previous report demonstrated that 
cultures of B. avium were consistently resistant to penicillin 
and cefuroxime but susceptible to mezlocillin, piperacillin, 
gentamicin, amikacin, and cefoperazone (6). Although B. 
avium has been shown to share several virulence factors 
with B. pertussis, B. parapertussis, and B. bronchiseptica, 
it does not carry genes that encode pertussis toxin or adeny-
late cyclase toxin (7). B. avium and B. avium–like organ-
isms have yet-unidentiﬁ  ed virulence factors, which may 
contribute to their ability to cross over from an animal host 
to an opportunistic human pathogen.
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Figure. 16S rRNA dendrogram. Phylogenetic tree of relationships 
among Bordetella spp. inferred on the basis of aligned 16S rRNA 
gene sequences from type strains (ﬁ   rst 500 bp); a neighbor-
joining algorithm with Achromobacter xylosoxidans xylosoxidans 
is used as an outgroup. B. avium, ATCC35086; B. bronchiseptica, 
ATCC19395; B. hinzii, ATCC51783; B. holmseii, ATCC51541; B. 
parapertussis, ATCC15311; B. pertussis, ATCC9340; B. trematum, 
DSM11334. Scale bar, indicates percentage genetic distance.Staphylococcus aureus (MRSA) surveillance at the Veterans Af-
fairs Medical Center in Seattle. Her current research is focused on 
the use of molecular diagnostics in the epidemiology of MRSA 
infection.
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